We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 33.02 | 11.86% | 311.41 | 311.40 | 320.00 | 322.54 | 308.68 | 313.42 | 9,644,684 | 05:00:03 |
From Nov 2023 to May 2024
By Colin Kellaher
Amgen has hired James Bradner as executive vice president of research and development and chief scientific officer of the biotechnology company.
Amgen on Thursday said Bradner has been a clinician at the Dana-Farber Cancer Institute for the past year after a stint as president of the Novartis Institutes for BioMedical Research, where he was a member of the executive committee of Swiss drugmaker Novartis.
Amgen said Bradner succeeds David Reese, who is taking on the newly created post of executive vice president and chief technology officer, and will be responsible for accelerating the use of technology and artificial intelligence across all facets of the Thousand Oaks, Calif., company.
Bradner, meanwhile, will be responsible for advancing Amgen's pipeline and its worldwide research efforts.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 14, 2023 09:38 ET (14:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
